INCY Incyte Genomics Inc Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:15
Aug 04
Aug 04
Earnings beat with expanding drug pipeline.
Incyte reported Q4 revenue of $1.67B and adjusted earnings of $3.09, crushing the $2.12 estimate, and raised full-year net sales guidance. The company, once seen as a one-drug name, now has a pipeline of 9–10 drugs in various stages of trials, all of which could be major winners. Technically, traders can watch the $109 area (50-day) as an alert, investors can use the 200-day near $101, with the uptrend over above $100.
HIGH
11:35
Jul 29
Jul 29
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks.
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks including ABBV, KO, and F in a broad round of analyst upgrades.
12:00
Jul 28
Jul 28
The overall guidance tone is confident with raised revenue guidance for the year, reflecting broad-based strength across the portfolio and a stronger pipeline.
HIGH
20:12
Jun 19
Jun 19
Speaker cites INCY as actively seeking an immunology acquisition.
Speaker cites INCY as actively seeking an immunology acquisition, flagging NKTR as a potential target; no direct INCY directional view stated.
LOW
15:38
Jun 08
Jun 08
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions.
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions; mentioned as potential acquirer of NKTR, no direct directional view on INCY itself stated.
MED
11:42
Jun 08
Jun 08
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its.
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its hematology portfolio into bleeding disorders.
12:00
Apr 28
Apr 28
Management conveys strong confidence in the company's trajectory, with net sales up 20%, a strong pipeline, and multiple upcoming regulatory milestones. The tone is optimistic, and they reaffirm full-year guidance while highlighting the potential of new product launches.
HIGH
01:10
Mar 08
Mar 08
The failure to win a key FDA label expansion is a direct negative catalyst for the stock.
The failure to win a key FDA label expansion is a direct negative catalyst for the stock, impacting future revenue streams.
MED
08:24
Feb 20
Feb 20
The trade is long Incyte based on the continued strength of its ruxolitinib franchise.
The trade is long Incyte based on the continued strength of its ruxolitinib franchise and strong expected sales growth for its drug Opzelura.
MED
13:00
Feb 10
Feb 10
Management guided revenues up 10-13% and emphasized multiple late-stage pipeline catalysts (Monjuvi, Povacitinib, KRAS G12D, etc.) that could triple the top line. The long-term strategy to replace the Jackify franchise with diversified core growth underpins the bullish tone.
HIGH
About INCY Analyst Coverage
Buzzberg tracks INCY (Incyte Genomics Inc) across 6 sources. 1 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (9%). 11 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: Josh Brown, DeItaone, Bill.